In the Margins

Valeant names hedge fund partner to board

October 26, 2015

By Forbes

Valeant Pharmaceuticals has named Mason Morfit, a partner at activist hedge fund ValueAct Capital, to its board of directors. Morfit previously served on the embattled specialty drugmaker's board from 2007 to 2014; ValueAct is one of Valeant's largest shareholders. Read the original story from Forbes

 

 

Most Read

A Seat at the Table
IDC's Kim aims to expand, improve membership

In his new role heading up Independent Directors Council, Thomas Kim plans to focus on the group's core mission while expanding its presence and influence. "As ...